We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the second announcement this week of a large drugmaker acquiring a rare diseases-focused company, Merck has agreed to buy Accleron Pharma for $11.5 billion to strengthen its cardiovascular pipeline. Read More
The companies said their method enlarges the number of possible antigen targets, which could lead to cancer immunotherapies for a broader range of patients and cancer types. Read More
Hospitals that take part in the 340B drug discount program almost quadrupled the price of cancer drugs in bills to patients with private insurance. Read More
Manufacturing is set to begin next year, when Emergent will begin production of “tens of millions of doses” of Providence’s investigational messenger RNA-based vaccine. Read More